AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39360368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 39360368 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 60
Study 39360440 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 421
Study 39360440 — intervention group
Group type: COMPARATOR
Intervention: iGlar
Number of subjects: 421
Study 39360568 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural interventions
Number of subjects: 17478
Study 39360568 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 17478
Study 39360568 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial (personalised) education
Number of subjects: 17478
Study 39360568 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple component education
Number of subjects: 17478
Study 39360568 — intervention group
Group type: EXPERIMENTAL
Intervention: Single topic education
Number of subjects: 17478
Study 39360568 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological plus educational interventions (Motivational interviewing/coaching + multifactorial education)
Number of subjects: 17478
Study 39360929 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 30
Study 39360943 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Number of subjects: 0
Study 39360943 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 0
Study 39360949 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 149
Study 39360949 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 149
Study 39361091 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Program (walking and exercises) for 12 weeks
Number of subjects: 86
Study 39361091 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 86
Study 39361218 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 therapy
Number of subjects: 55
Study 39361227 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based weight loss intervention over 24 weeks
Number of subjects: 112
Study 39361227 — intervention group
Group type: COMPARATOR
Intervention: Cohabitating dyads
Number of subjects: 112
Study 39361227 — intervention group
Group type: COMPARATOR
Intervention: Non-cohabitating dyads
Number of subjects: 112
Study 39361293 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth closure during sleep by applying pressure to the mentum until teeth are in occlusion
Number of subjects: 54
Study 39361293 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth closure in patients with near-zero mouth breathing
Number of subjects: 54
Study 39361293 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth closure in patients with moderate levels of mouth breathing
Number of subjects: 54
Study 39361293 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth closure in patients with high levels of mouth breathing
Number of subjects: 54
Study 39361293 — intervention group
Group type: EXPERIMENTAL
Intervention: Velopharyngeal obstruction
Number of subjects: 54
Study 39361311 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP plus shock
Number of subjects: 2595
Study 39361311 — intervention group
Group type: COMPARATOR
Intervention: Shock only
Number of subjects: 2595
Study 39361572 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac prehabilitation/rehabilitation/education (CREED AF) intervention
Number of subjects: 106
Study 39361572 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 106
Study 39361597 — intervention group
Group type: EXPERIMENTAL
Intervention: JanaCare Aina Blood Monitoring System (JCAina)
Number of subjects: 0
Study 39361597 — intervention group
Group type: EXPERIMENTAL
Intervention: Tascom SimplexTAS 101 device (TAS101)
Number of subjects: 0
Study 39361705 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB)
Number of subjects: 0
Study 39361705 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 0
Study 39361914 — intervention group
Group type: EXPERIMENTAL
Intervention: Countermarketing messages
Number of subjects: 0
Study 39361914 — intervention group
Group type: COMPARATOR
Intervention: Health education messages
Number of subjects: 0
Study 39361946 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care chemotherapy (SOC) - once weekly paclitaxel, topotecan, or pegylated liposomal doxorubicin
Number of subjects: 562
Study 39361946 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib/olaparib
Number of subjects: 562
Study 39361946 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib
Number of subjects: 562
Study 39362046 — intervention group
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (ONTAK) at 5 μg/kg
Number of subjects: 10
Study 39362046 — intervention group
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (ONTAK) at 15 μg/kg
Number of subjects: 10
Study 39362046 — intervention group
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (ONTAK) at 25 μg/kg
Number of subjects: 10
Study 39362046 — intervention group
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (ONTAK)
Number of subjects: 10
Study 39362248 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziftomenib (50-1000 mg) orally once daily in 28-day cycles (Phase 1a)
Number of subjects: 83
Study 39362248 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziftomenib (600 mg) in Phase 1b
Number of subjects: 83
Study 39362248 — intervention group
Group type: COMPARATOR
Intervention: Ziftomenib (200 mg) in Phase 1b
Number of subjects: 83
Study 39362249 — intervention group
Group type: EXPERIMENTAL
Intervention: Capmatinib (400 mg orally twice daily)
Number of subjects: 373
Study 39362630 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching intervention (≤6 live virtual coaching sessions)
Number of subjects: 28
Study 39362630 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching intervention (WHO Wellbeing Index (WHO-5))
Number of subjects: 28
Study 39362630 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching intervention (Perceived Stress Scale (PSS))
Number of subjects: 28
Study 39362630 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching intervention (Utrecht Work Engagement Scale (UWES))
Number of subjects: 28
Study 39362749 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection with acetic acid (VIA)
Number of subjects: 878
Study 39362749 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection with acetic acid (VIA) with iodine
Number of subjects: 878
Study 39362749 — intervention group
Group type: COMPARATOR
Intervention: Visual inspection without iodine
Number of subjects: 878
Study 39362749 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection with iodine
Number of subjects: 878
Study 39362749 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV positive status
Number of subjects: 878
Study 39362795 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula milk and feeding accessories
Number of subjects: 419
Study 39362795 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (BF)
Number of subjects: 419
Study 39362795 — intervention group
Group type: COMPARATOR
Intervention: Non-breastfeeding (non-BF) mothers' diet
Number of subjects: 419
Study 39362907 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage (MLD) administered from 180 to 195 minutes
Number of subjects: 15
Study 39362933 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab
Number of subjects: 209
Study 39362933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 39363095 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy
Number of subjects: 0
Study 39363095 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin therapy
Number of subjects: 0
Study 39363095 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus testosterone
Number of subjects: 0
Study 39363095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39363100 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline post-exposure prophylaxis (200-mg dose taken after condomless sex)
Number of subjects: 150
Study 39363100 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 150
Study 39363201 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrolides (azithromycin) for 5 days
Number of subjects: 376
Study 39363201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376
Study 39363230 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypoxia with cognitive training
Number of subjects: 180
Study 39363230 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 180
Study 39363243 — intervention group
Group type: EXPERIMENTAL
Intervention: Givosiran
Number of subjects: 16
Study 39363246 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin allergy assessment pathway
Number of subjects: 0
Study 39363246 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 0
Study 39363320 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy
Number of subjects: 857
Study 39363320 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored treatment based on resistance mechanism
Number of subjects: 857
Study 39363320 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-derived xenografts (PDX)
Number of subjects: 857
Study 39363320 — intervention group
Group type: EXPERIMENTAL
Intervention: PDX models for various cancers
Number of subjects: 857
Study 39363376 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week aerobic exercise training program (12 supervised sessions on a cycling ergometer)
Number of subjects: 24
Study 39363376 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 24
Study 39363383 — intervention group
Group type: EXPERIMENTAL
Intervention: TranS-C + MSI
Number of subjects: 178
Study 39363383 — intervention group
Group type: COMPARATOR
Intervention: TranS-C alone
Number of subjects: 178
Study 39363801 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen Immunotherapy (AIT)
Number of subjects: 0
Study 39363801 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of AIT and biologics
Number of subjects: 0
Study 39364270 — intervention group
Group type: EXPERIMENTAL
Intervention: NACRT (n=25)
Number of subjects: 45
Study 39364270 — intervention group
Group type: COMPARATOR
Intervention: NACT (control, n=20)
Number of subjects: 45
Study 39364271 — intervention group
Group type: EXPERIMENTAL
Intervention: Infected volunteers (n=18)
Number of subjects: 34
Study 39364271 — intervention group
Group type: COMPARATOR
Intervention: Uninfected volunteers (n=16)
Number of subjects: 34
Study 39364754 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye-tracking training for 20 sessions over 9 months
Number of subjects: 40
Study 39364754 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 40
Study 39364857 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic Resistance Training (PRT)
Number of subjects: 55
Study 39364857 — intervention group
Group type: COMPARATOR
Intervention: Continuous Resistance Training (CRT)
Number of subjects: 55
Study 39364876 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallstone disease
Number of subjects: 3480
Study 39364940 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRHa) therapy
Number of subjects: 814
Study 39365190 — intervention group
Group type: EXPERIMENTAL
Intervention: High-concentration (4.5%) HA-based filler with hybrid cooperative complexes (HCC)
Number of subjects: 28
Study 39365383 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Assist Maneuver (LAM) during Neurally Adjusted Ventilatory Assist (NAVA) and Neural Pressure Support (NPS)
Number of subjects: 10
Study 39365383 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Assist Maneuver (LAM)
Number of subjects: 10
Study 39365384 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolization
Number of subjects: 140
Study 39365384 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 140
Study 39365384 — intervention group
Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 140
Study 39365384 — intervention group
Group type: EXPERIMENTAL
Intervention: OIS grade 4 or 5 splenic trauma
Number of subjects: 140
Study 39365384 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial leak
Number of subjects: 140
Study 39365384 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoaneurysm
Number of subjects: 140
Study 39365384 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudocyst
Number of subjects: 140
Study 39365658 — intervention group
Group type: EXPERIMENTAL
Intervention: I-InTERACT-North web-based stepped-care parent support program
Number of subjects: 244
Study 39365658 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 244
Study 39365895 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact fish skin graft
Number of subjects: 255
Study 39365895 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 255
Study 39365957 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET-guided adaptive treatment (mean 71 Gy in 30 fractions, mean lung dose 17.9 Gy)
Number of subjects: 127
Study 39365957 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (60 Gy/30 fractions)
Number of subjects: 127
Study 39365960 — intervention group
Group type: EXPERIMENTAL
Intervention: Glofitamab monotherapy with obinutuzumab pretreatment (Gpt) 1,000 or 2,000 mg 7 days before glofitamab; glofitamab step-up dosing on days 8 (2.5 mg) and 15 (10 mg) of cycle 1, target dose of 16 or 30 mg once every 3 weeks from cycle 2 day 1 onward, for 12 cycles.
Number of subjects: 61
Study 39365990 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Training (PT)
Number of subjects: 112
Study 39365990 — intervention group
Group type: COMPARATOR
Intervention: Free Training (FT)
Number of subjects: 112
Study 39365990 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups together
Number of subjects: 112
Study 39365992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 10mg twice daily for up to 12 cycles
Number of subjects: 49
Study 39366004 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced carbohydrate diet (RCHO)
Number of subjects: 0
Study 39366004 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39366028 — intervention group
Group type: EXPERIMENTAL
Intervention: One of the three dietary patterns of the US Dietary Guidelines
Number of subjects: 63
Study 39366028 — intervention group
Group type: EXPERIMENTAL
Intervention: Another dietary pattern of the US Dietary Guidelines
Number of subjects: 63
Study 39366028 — intervention group
Group type: EXPERIMENTAL
Intervention: The third dietary pattern of the US Dietary Guidelines
Number of subjects: 63
Study 39366028 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 63
Study 39366276 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger particle size oat flour
Number of subjects: 20
Study 39366276 — intervention group
Group type: COMPARATOR
Intervention: Finely milled oat flour (control)
Number of subjects: 20
Study 39366468 — intervention group
Group type: EXPERIMENTAL
Intervention: CP101
Number of subjects: 198
Study 39366468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 39366653 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral sphenopalatine ganglion block (SPGB) with 5 mL lidocaine 2% on each side (G1)
Number of subjects: 120
Study 39366653 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia and bilateral saline injection of 5 mL on each side (G2)
Number of subjects: 120
Study 39366722 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methotrexate (MTX) initiated and increased to maximum tolerated dose by week 12
Number of subjects: 300
Study 39366722 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued MTX dose with subcutaneous adalimumab
Number of subjects: 300
Study 39366722 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher MTX-PGs concentration
Number of subjects: 300
Study 39366722 — intervention group
Group type: EXPERIMENTAL
Intervention: Total MTX-PGs concentration
Number of subjects: 300
Study 39366745 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (antenatal care)
Number of subjects: 500
Study 39366745 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care group
Number of subjects: 500
Study 39366751 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib monotherapy
Number of subjects: 0
Study 39366752 — intervention group
Group type: EXPERIMENTAL
Intervention: HBM4003 0.3 mg/kg plus toripalimab 240 mg every 3 weeks
Number of subjects: 40
Study 39367057 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting-state functional magnetic resonance imaging (rsfMRI) assessment
Number of subjects: 544
Study 39367057 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimensional analyses
Number of subjects: 544
Study 39367230 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent oro-esophageal tube feeding (IOE)
Number of subjects: 82
Study 39367230 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric tube feeding (NGT)
Number of subjects: 82
Study 39367230 — intervention group
Group type: EXPERIMENTAL
Intervention: IOE
Number of subjects: 82
Study 39367230 — intervention group
Group type: COMPARATOR
Intervention: NGT
Number of subjects: 82
Study 39367366 — intervention group
Group type: EXPERIMENTAL
Intervention: ASSIP (Attempted Suicide Short Intervention Program) plus treatment as usual
Number of subjects: 0
Study 39367366 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 39367394 — intervention group
Group type: EXPERIMENTAL
Intervention: Milled Co-Cr bar
Number of subjects: 20
Study 39367394 — intervention group
Group type: COMPARATOR
Intervention: Selective laser melted (SLM) Co-Cr bar
Number of subjects: 20
Study 39367394 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 39367399 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART subgroup (silver modified atraumatic restorative technique)
Number of subjects: 28
Study 39367399 — intervention group
Group type: COMPARATOR
Intervention: CONV subgroup (high viscosity glass ionomer restoration and fluoride varnish application)
Number of subjects: 28
Study 39367399 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART subgroup
Number of subjects: 28
Study 39367399 — intervention group
Group type: COMPARATOR
Intervention: CONV subgroup
Number of subjects: 28
Study 39367427 — intervention group
Group type: EXPERIMENTAL
Intervention: TauroPace™ (TP)
Number of subjects: 1170
Study 39367439 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention using videoconferencing technology for linking incarcerated women to community MOUD treatment.
Number of subjects: 0
Study 39367450 — intervention group
Group type: EXPERIMENTAL
Intervention: CHV-NEO messaging integrated into eCHIS
Number of subjects: 7200
Study 39367450 — intervention group
Group type: COMPARATOR
Intervention: Standard of care using eCHIS without CHV-NEO
Number of subjects: 7200
Study 39367450 — intervention group
Group type: EXPERIMENTAL
Intervention: CHV-NEO messaging
Number of subjects: 7200
Study 39367452 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung and diaphragm protective ventilation
Number of subjects: 222
Study 39367452 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 222
Study 39367488 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental questionnaires measuring developmental levels in language and social-emotional domains, parental mental well-being, life events, parenting stress, parenting styles, and family relationships.
Number of subjects: 1000
Study 39367488 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral assessments using Griffiths Development Scales and Wechsler Preschool and Primary Scale of Intelligence.
Number of subjects: 1000
Study 39367488 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior observation experiments targeting behavioral inhibition, compliance, self-control, and social-emotional regulation.
Number of subjects: 1000
Study 39367749 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip strength (HGS) measured using a hand dynamometer.
Number of subjects: 64
Study 39367749 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulse oscillometry for evaluating SAD, defined as R5-R20 ⩾0.07 kPa/L/s.
Number of subjects: 64
Study 39368033 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigh breaths during pressure support ventilation (PSV)
Number of subjects: 56
Study 39368033 — intervention group
Group type: COMPARATOR
Intervention: No Sigh during pressure support ventilation (PSV)
Number of subjects: 56
Study 39368039 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucatinib (300 mg twice daily)
Number of subjects: 283
Study 39368039 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants (control group)
Number of subjects: 283
Study 39368068 — intervention group
Group type: COMPARATOR
Intervention: Hypertensive group
Number of subjects: 1055
Study 39368130 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric COVID-19 vaccine uptake influenced by concerns and misinformation surrounding the new vaccine.
Number of subjects: 0
Study 39368130 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric COVID-19 vaccine uptake influenced by witnessing others' vaccine and pandemic experiences.
Number of subjects: 0
Study 39368130 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric COVID-19 vaccine uptake influenced by participation in social activities.
Number of subjects: 0
Study 39368130 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric COVID-19 vaccine uptake influenced by the politicization of and political climate surrounding the vaccine.
Number of subjects: 0
Study 39368130 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric COVID-19 vaccine uptake influenced by health education surrounding the vaccines.
Number of subjects: 0
Study 39368335 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle Hatha and Restorative Yoga, performed two to three times per week for four weeks at a low to moderate level of intensity.
Number of subjects: 177
Study 39368459 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT-Email
Number of subjects: 57